AVITA Medical to Announce Second Quarter 2025 Financial Results

Core Insights - AVITA Medical, Inc. will report its second quarter 2025 financial results on August 7, 2025, after U.S. market close [1] - A conference call and webcast will be held on the same day to discuss financial results and business highlights [1] Company Overview - AVITA Medical is a leading therapeutic acute wound care company focused on delivering transformative solutions [3] - The company's flagship product, the RECELL System, is FDA-approved for treating thermal burn wounds and full-thickness skin defects, utilizing a patient's own skin to create Spray-On Skin Cells [3] - In the U.S., AVITA Medical has exclusive rights to manufacture and distribute PermeaDerm®, a biosynthetic wound matrix, and Cohealyx™, a collagen-based dermal matrix [3] International Market Presence - The RECELL System is approved for various applications in international markets, including burns and full-thickness skin defects [4] - The system is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan [4]